NCT07895498 · Memorial Sloan Kettering Cancer Center
A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
What this study is about
The researchers are doing this study to find out whether the combination of ivermectin and the usual treatment prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity).
View original scientific description
The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Interventions
DRUG
Minocycline
Minocycline 100mg PO twice daily (or doxycycline alternative)
DRUG
Hypochlorous Acid
Face: Hypochlorous acid solution applied every morning
DRUG
Hydrocortison cream
Face: Hydrocortisone 2.5% cream (or equivalent) applied twice daily
DRUG
Triamcinolone (TAC) 0.1% cream
Trunk: Triamcinolone 0.1% cream (or equivalent) applied twice daily
DRUG
Clobetasol
Scalp: Clobetasol propionate 0.05% solution (or equivalent) applied twice daily
OTHER
Photoprotection
Broad-spectrum sunscreen (SPF 30 or higher) applied daily to sun- exposed areas
DRUG
Ivermectin
Ivermectin 200mcg/kg orally weekly PLUS
Primary outcome measures
pustular drug eruption assessed
Time frame: Day 56 ± 3 days
using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Rash severity will be categorized into four ordered levels (grade 0, grade 1, grade 2, and grade 3), where lower grades indicate less severe disease involvement.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
- Female or male aged 18 years and older at the time of enrollment.
- Not pregnant and not nursing.
- No active infection requiring parenteral antibiotic(s).
- Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib
- No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients).
- Patients who are able to understand and willing to sign the written informed consent form or patients who have impaired decision-making capacity but have a legally authorized representative who can consent on their behalf are eligible. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
Exclusion criteria
- Concurrent use of another investigational drug or device for the daraxonrasib-induced skin toxicity (i.e., outside of study treatment) during, or within 4 weeks of study treatment.
- Patients receiving prednisone 10 mg/day or higher (or equivalent) at the time of randomization for indications other than daraxonrasib skin toxicity management.
- Patients receiving tetracyclines, ivermectin or other systemic medication that could mask daraxonrasib rash development.
- Pregnancy or planned pregnancy during the study period.
- Documented allergy to oral ivermectin and / or minocycline
- Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation.
Where
- Basking Ridge, New Jersey
- Middletown, New Jersey
- Montvale, New Jersey
- Commack, New York
- Harrison, New York
- New York, New York
- Uniondale, New York
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 26, 2026 · Source of record for eligibility and locations